Kornimate/medical-research-clean huggingface dataset:
nutrition, health and quality of life: development of new formulations of traditional products of the "made in italy" diet optimized for consumers with an age over 50 years (miao 50)

Conditions: Aging

Summary: the study ""nutritional trial with fortified milk in 65+ years old subjects" is a part of a complex research project and multi-sectoral development (miao 50) with the participation of university research institutes and small and medium italian enterprises. the general objective of the call is to promote the collaboration between the best scientific knowledge, both epidemiological and experimental, and the most advanced technologies to develop foods with a nutritional profile adequate to the needs of consumers with an age over 50 years old, which are easy to use and make it possible to eat in a healthy manner, complete and balanced and also meets the quality and flavors of traditional italian.

aging is associated with a functional decline of most physiological systems including the immune system. it could be hypothesized that an inadequate nutritional status may amplify the effects of a low-grade chronic inflammation associated with age influencing the functionality of the immune systems, the resistance to infections, the cognitive function and contributing to an increased morbidity and mortality. indeed experimental evidence indicate that improving the nutritional status attenuates the decline in immune and cognitive functions, in physical performance associated with age by helping to improve the level of quality of life. therefore, the present study focus on nutrients and micronutrient which have a role in fighting oxidative stress, in the regulation of inflammatory responses and the immune system.

Eligibility criteria:
inclusion criteria: * subjects with an age between 63 and 80 years old, males and females, free-living, resident in bologna and its province. exclusion criteria: * allergy or intolerance to cow's milk or a dislike. dietary treatments and use of specific supplements of molecules associated with the proposed intervention up to two months before the start of the trial. presence of celiac disease and other malabsorption. presence of disease with poor prognosis in the short term. chronic therapy with anticoagulants, corticosteroids, and anti-cancer. exclusion of subjects with onset of chronic-degenerative diseases in the last year, presence of type i diabetes and chronic viral hepatitis.

Keywords: fortified milk, aging, health status
effect of desflurane on cardiac function during cardiac surgery: tissue doppler imaging of mitral valve annular velocity

Conditions: Valvular Heart Disease

Summary: the purpose of this study is to determine desflurane's dose-dependent effect on left ventricular (lv) function in cardiac surgery. the change of tissue doppler imaging (tdi) of lateral mitral valve annular velocity at three different desflurane concentrations would be analyzed by using intraoperative transesophageal echocardiography (tee) in cardiac surgery patients

tissue doppler imaging (tdi ) of mitral annular velocity during the cardiac cycle has been introduced as a reliable method for analysis of systolic and diastolic lv ling-axix function , efficacy of diastolic tdi profile, including early early relaxation (e') and atrial contraction (a') and has been suggested to be useful in predicting the postoperative clinical outcomes and the impact of isoflurane on lv diastolic function. desflurane is widely used in cardiac surgery patients due to its beneficial effects , but many studies have shown that desflurane reduces myocardial contractility in a dose-dependent manner, and compromises left ventricular( lv) function we hypothesized that desflurane , even at a clinical dosage, would affects intraoperative lv systolic function in a dose-dependent manner and thus produce significant changes int the tdi profiles of mitral annular velocity. so we planned to study the changes in tdi profiles of lateral mitral annular velocity at the clinical desflurane dosage during remifentanil based anesthesia for cardiac surgery

Eligibility criteria:
ages eligible for study : 20 years to 65 years genders eligible for study : both inclusion criteria: * patients undergoing cardiac surgery exclusion criteria: * low ejection fraction \<50% in preoperative transthoracic echocardiography * atrial fibrillation * pacemaker * pericardial and infiltrative myocardial disease * mitral annular calcification, surgical rings, prosthetic mitral valves * lateral left ventricular regional wall motion abnormality * esophageal spasm, stricture, laceration, perforation, and diverticulum * diaphragmatic hernia * history of extensive radiation to mediastinum * upper gastrointestinal bleeding

Keywords: desflurane, mitral annular velocity, tissue doppler imaging
comparison of quadriceps and semitendinosus grafts in acl reconstruction using data from the danish knee ligament reconstruction registry (dkrr)

Conditions: Anterior Cruciate Ligament Injury; Knee Injury; Ligament Reconstruction; Sports Injuries

Summary: this study looks at two different types of tendon (tissue) used in knee surgery to repair a torn anterior cruciate ligament (acl), which is a common injury in active people. the two types are taken from different muscles in the thigh: one from the front (quadriceps) and one from the back (semitendinosus). we will use information already collected in a national health registry to see how patients recover after surgery. the study will compare knee function, activity level, and how often patients need another operation.

this is a retrospective observational cohort study based on data from the danish knee ligament reconstruction registry (dkrr). the study includes patients who underwent primary acl reconstruction using either a quadriceps tendon graft (with or without a bone block) or a quadrupled semitendinosus tendon graft. the primary outcome measures are the knee injury and osteoarthritis outcome score (koos) and the tegner activity scale. secondary outcomes include reoperation rates, postoperative complications, and patient satisfaction. all available demographic, operative, and patient-reported outcome data will be analyzed. multivariable regression will be used to adjust for confounders such as age, sex, bmi, time from injury to surgery, and surgeon volume. the study is exempt from ethical approval under danish law, and data will be handled in compliance with gdpr.

Eligibility criteria:
inclusion criteria: * primary acl reconstruction registered in the danish knee ligament reconstruction registry (dkrr) * known graft type: quadriceps tendon or semitendinosus tendon minimum 1-year follow-up with completed patient-reported outcome measures (koos and/or tegner score) * age between 15 and 50 years at the time of surgery (optional subgroup analysis) exclusion criteria: * revision acl reconstruction * multiligament knee reconstruction * missing or incomplete proms or key clinical data

Keywords: acl reconstruction quadriceps tendon graft semitendinosus graft dkrr knee ligament injury orthopaedic surgery registry study
survival model for preterm infants

Conditions: Mortality; Morbidity;Newborn

Summary: study title predictive model of mortality and major morbidity in preterm neonates in the perinatal period internal ref. no. / short title survival model study design observational population-based cohort study planned sample size retrospective analysis of database planned study duration 6-months primary objectives to derive a mathematical model for predicting mortality and the composite of mortality/major-morbidity before and immediately after birth in preterm infants secondary objectives statistical methodology and analysis mixed-model multivariable logistic regression analysis


Eligibility criteria:
inclusion criteria: 1. preterm infants born alive at or less than 34 weeks of gestation. 2. born in welsh maternity and admitted for care to a welsh neonatal unit. 3. mother normally resident in wales exclusion criteria 1. the mother is normally resident in england (detailed maternal data not available) 2. congenital anomaly noted at birth (alters the natural probability of outcomes) 3. duplicate episodes for an individual infant
efficacy parecoxib and ketorolac as preemptive analgesia in spine fusion

Conditions: Postoperative Pain

Summary: the purpose of this study is to evaluate the efficacy of parecoxib and ketorolac as a preemptive analgesia in patients undergoing lumbar spinal fusion.

a prospective, double-blinded randomized control trial. randomly allocated patient undergoing posterior lumbar spinal fusion into 3 groups (n=32) to receive parecoxib, ketorolac and placebo around 30 minutes prior to incised skin. efficacy was assessed by visual analog scale score (0-10), total opioid consumption, complication and bleeding also recorded.

Eligibility criteria:
inclusion criteria: * patients undergoing lumbar spinal fusion for one to three levels * asa class i or ii exclusion criteria: * history of allergy to sulfa group * history of allergy to opoid or nsaids * contraindicate to nsaids use * history of coagulopathy or platelet disfunction

Keywords: preemptive analgesia lumbar fusion parecoxib ketorolac
dose-escalation study of gimatecan administered in two different schedules in adult patients with advanced solid tumors

Conditions: Solid Tumors

Summary: this study will evaluate the maximum tolerated dose and dose limiting toxicity of gimatecan administered orally in patients with advanced solid tumors


Eligibility criteria:
inclusion criteria: * advanced or metastatic cancer * 18 years and above exclusion criteria: * previous treatment with 4 or more cycles of carboplatin; * previous treatment with 2 or more courses of nitrosourea or mitomycin; * previous radiation therapy greater than or equal to 25% of the hematopoietic reserve; * severe and/or uncontrolled medical conditions other protocol-defined inclusion/exclusion criteria may apply

Keywords: maximum tolerated dose solid tumors dose limiting toxicity topoisomerase-1 inhibitor
liver resection for patients with hepatocellular carcinoma and impaired liver function

Conditions: Hepatic Cancer

Summary: hepatic dysfunction limits the therapeutic options for hepatocellular carcinoma (hcc), which is closely associated with patient prognosis. established practice guidelines for patients with hcc and impaired liver function are lacking. the treatment allocation in these populations is heterogeneous and remains controversial. this study compared the survival benefits of liver resection (lr) and transarterial chemoembolisation (tace) in patients with hcc and impaired liver function.


Eligibility criteria:
inclusion criteria: * patients with hcc who received conventional lr or tace exclusion criteria: * （1） presence of portal vein tumour thrombosis (pvtt), hepatic artery, biliary duct or inferior vena cava invasion * （2） extrahepatic spread (ehs) * （3） albumin-bilirubin grade 1 or 3 * （4） eastern cooperative oncology group performance status (ecog-ps) \>1 * （5） tumour number \>3 * （6） other tumours or severe cardiac, cerebral, and renal insufficiency * （7）ascites, hepatic encephalopathy, and jaundice
absorb bvs vs. drug coated balloon for treatment of isr

Conditions: Coronary Artery Disease; Coronary Restenosis

Summary: absorbisr is a randomized, controlled trial, single center, prospective, not blinded to evaluate two strategies of in stent restenosis treatment: implantation of drug eluting bioresorbable stent scaffold absorb® vs. balloon angioplasty with drug eluting balloon sequent please®.

this is randomized-controlled trial of absorb® bioresorbable vascular scaffold (bvs) vs. sequent please® drug coated balloon in an all-comers population with in-stent-restenosis (isr). the patients will be randomized in a 1:1 fashion and the investigators intend to include 150 patients. all patients presenting with isr and requiring percutaneous coronary intervention will be eligible to be included in this study. this will include patients with stable angina and those presenting with acute coronary syndrome (acs). the primary objective of this study is to demonstrate superiority of the absorb® bioresorbable scaffold compared to the sequent please® drug coated balloon when treating patients with in-stent-restenosis regards to primary endpoint - angiographic late lumen loss at 9 month follow-up.

Eligibility criteria:
inclusion criteria: * participant is willing and able to give informed consent for participation in the study. * male or female, aged 18 years or above. * diagnosed with isr requiring percutaneous coronary intervention: visual diameter stenosis \> 70 % and/or fractional flow reserve \< 0.81 and/or non-invasive testing demonstrating ischemia. this real-life population with in-stent restenosis beside typical stable patients with isr includes acs patients with thrombus containing lesions, patients with multivessel disease, patients with isr in non-infarct related artery, with isr in bare metal stent (bms), drug eluting stent (des) or bioresorbable vascular scaffold (bvs), isr in lesion previously treated by plain old balloon angioplasty (poba), drug eluting balloon (deb) or additional stent implantation. * double anti-platelet therapy for the duration of at least 12 months is considered possible at the time of intervention exclusion criteria: * the participant may not enter the study if the interventionist has doubts that he is not able to deliver and implant the absorb scaffold (e.g. highly calcified lesions). * patients who have any contraindications for using deb (seqent please) or bvs (absorb) specified in instructions for use are not able to participate in this study. * women with childbearing potential must have a negative result of pregnancy test and they must use an effective contraception method for at least 12 months after study procedure.

Keywords: bioresorbable vascular scaffold absorb drug eluting balloon percutaneous coronary intervention
ocular blood flow in colorectal cancer patients

Conditions: Metastatic Colorectal Cancer

Summary: in colorectal cancer therapy anti-angiogenic strategies have become a cornerstone of treatment regimens in the metastatic setting. addition of bevacizumab to conventional chemotherapeutic combination regimens has improved the median overall survival of advanced colorectal cancer patients by approximately 5 months. selecting patients, who will benefit from anti-angiogenic approaches, would be highly desirable in order to optimize treatment strategies. changes in ocular blood flow may be an attractive biomarker for predicting treatment response. in light of the given alternative first line treatment options such a predictive biomarker would be of clinical benefit. in the proposed study the investigators will assess potential changes in the ocular blood flow of mcrc patients after treatment with standard of care anti-angiogenic/cytotoxic therapy as an early predictive marker of treatment response as assessed by standard ct-scan


Eligibility criteria:
inclusion criteria: * male or female patients (age 18 and over) suffering from mcrc. * normal findings in ophthalmic examination (except the investigator finds an abnormality irrelevant for the purpose of the study.) * patients, which are scheduled for standard of care treatment with chemotherapy plus bevacizumab exclusion criteria: * refusal to give informed consent * severe hypertension (rr ≥180/110) * epilepsy * pregnancy and breastfeeding women
amis plus - national registry of acute myocardial infarction in switzerland

Conditions: Acute Coronary Syndrome

Summary: the amis plus national registry collects and analyzes data on patients with acute myocardial infarction in switzerland in the pre-admission, hospital and follow-up phases. emphasis is placed on the evaluation of risk factors, diagnostics, urgent therapy strategies and treatment of acute coronary syndrome. the amis plus data gathered are important for assessing guidelines, improving compliance with guidelines in clinical practice, investigating patient groups not extensively studied in large randomized trials, quality assurance as well as the continuous improvement of therapeutic strategies based on a large database.

the amis plus project has two main goals: 1. to maintain a nationwide registry * an ongoing nationwide registry (databank) of acute coronary syndromes * description of the patient population with acute coronary syndromes * description of characteristics of treatment and hospitalization * description of outcomes 3- and 12-months after admission for acs * epidemiological studies, e.g. definition of risk factors of patients with acute coronary syndromes, hospital mortality, time and cost-effective strategies as well as outcome measures 2. quality control * evaluation of compliance with guidelines for the medical care of acute coronary syndromes * internal quality control through regular feedback and benchmarking methods all swiss hospitals admitting patients with acute coronary syndrome are eligible. data are collected on demographics, risk factors, symptoms, laboratory results, invasive therapy, complications and medication. since the start in january 1997, the method of data collection has continuously improved in order to suit the different needs and technological advancements of the participating hospitals. participants can either complete paper questionnaires and send them directly to the amis plus data center at the institute of social and preventive medicine in zurich where these questionnaires are then checked and entered online or they can enter data directly online (amis online questionnaire). data security has a high priority. participant identification (code for hospital and physician) and a password are required to access the data entry form and send data.

Eligibility criteria:
inclusion criteria: patients who had symptoms within the last 48 hours at hospital admission with a discharge clinical diagnosis of acute myocardial infarction or patients who suffered an acute myocardial infarction in hospital during a hospitalization for other reasons. exclusion criteria: since january 2012, patients with unstable angina are no longer included.
the effects of tdcs on illness awareness in schizophrenia

Conditions: Schizophrenia

Summary: this is a novel study that seeks to explore the clinical and functional imaging effects of transcranial direct current stimulation (tdcs) on illness awareness or anosognosia in schizophrenia, arguably the most treatment-resistant manifestation of the disorder.

transcranial dcs is a novel, non-invasive and non-convulsive technique for altering brain function. to our knowledge, no research has investigated the functional and behavioural effects of tdcs on anosognosia in schizophrenia. as such, we aim to improve impaired illness awareness in schizophrenia with tdcs by inhibiting left hemisphere regions (i.e. temporoparietooccipital cortex) shown by our group to be activated during illness denial. positive results will demonstrate that impaired illness awareness in schizophrenia involves a similar brain network to impaired illness awareness in patients with brain lesions and can be similarly modulated with non-invasive techniques, such as tdcs. if proven effective, this easy to administer, safe, non-invasive intervention would have the potential to alter individuals' attitude towards their illness and medication, leading ultimately to an improvement in individuals' capacity for illness recognition and treatment engagement, which would undoubtedly have a significant impact on the management of this devastating mental disorder.

Eligibility criteria:
inclusion criteria: 1. male or female inpatients or outpatients ≥ 18 years of age 2. having a dsm-iv diagnosis of schizophrenia or schizoaffective disorder 3. voluntary and capable of consenting to participation in the research study 4. fluent in english 5. moderate-to-severe lack of illness awareness (≥3 on panss g12 insight and judgment item) 6. on a stable dose of antipsychotic and other concomitant medications, and unlikely to undergo changes in dose during the study exclusion criteria: 1. serious unstable medical illness or any concomitant major medical or neurological illness, including a history of seizures or a first degree relative with a history of a seizure disorder 2. acute suicidal and/or homicidal ideation 3. formal thought disorder rating of over 2 on the (scale for assessment of positive symptoms) saps. 4. dsm-iv substance dependence (except caffeine and nicotine) within one month prior to entering the study 5. pregnant women 6. mild lack of insight to good illness awareness (\<3 on panss g12 insight and judgment item). 7. positive urine drug screen for drugs of abuse 8. currently taking antiepileptics 9. any contraindications to mri (eg., metal implants that would preclude an mri, claustrophobia) 10. score \< 32 on the wide range achievement test-iii (wrat iii)

Keywords: magnetic resonance imaging anosognosia electrical stimulation of the brain
shuotongo ureteroscopy for upper urinary tract stones

Conditions: Urinary Calculi; Ureterocele

Summary: the purpose of this study is to use the shuotong ureteroscopy for surgical treatment of patients with upper urinary tract stones, taking advantage of the fact that the shuotong mirror can be used for simultaneous lithotripsy and stone removal, thus maximizing the discharge of stones from the body and improving the stone removal rate.

ureteroscopy via the natural lumen has the advantages of being non-invasive, safe and repeatable. this is where shuotongo ureteroscopy, a new type of ureteroscopy, has not yet become fully popular. usually, most patients with upper urinary tract stones are treated by ureteroscopy or with flexible ureteroscopy, because these endoscopes usually break the stones and ask the patient to drink more water to expel the stones by themselves, after the operation, it is usually easy to leave stones in the body, and some patients even form stone streets to block the ureter again after the operation. in some patients, stones may form again and obstruct the ureter again. the shuotong ureteroscopy has the advantages of stone crushing and stone removal, which can synchronize the process of stone crushing and stone removal and maintain a good surgical view. it has the advantages of simple operation, less trauma and high safety for the operation via natural channel, especially for the large stones in the upper urinary tract and gantun stones.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of ureteral calculus must be able to cooperate with the treatment exclusion criteria: * patients had severe urinary tract infections; patients had other conditions which investigators thought not suitable for the study.
two methods of diagnosing preterm labor

Conditions: Preterm Labor; Preterm Delivery

Summary: use of modern diagnostic tools e.g. fetal fibronectin and ultrasound measurement of cervical length to diagnose preterm labor can result in improved outcomes compared to traditional diagnosis based on digital examination to measure cervical change.

symptomatic preterm labor patients will be randomized to diagnosis of preterm labor by serial digital examination versus an algorithm incorporating transvaginal ultrasound measurement of cervical length and vaginal fetal fibronectin.

Eligibility criteria:
inclusion criteria: * symptomatic complaints suggestive of preterm labor * greater than 6 contractions per hour exclusion criteria: * multiple gestation * rupture of amniotic membranes * chorioamnionitis * congenital malformations * persistent vaginal bleeding * abruptio placentae * placenta previa * previously diagnosed short cervix \< 2.5 cm * cervical dilation \> 3 cm * cervical cerclage * exposure to tocolytic drugs * allergy or contraindication to nifedipine

Keywords: fibronectin cervical length